VRTX - Vertex Pharmaceuticals
397.27
| Index: | NDX, S&P 500 | P/E: | - | EPS (ttm): | -1.99 | Insider Own: | 0.24% | Shs Outstand: | 257.74M | Perf Week: | -14.33% |
| Market Cap: | 102.47B | Forward P/E: | 21.17 | EPS next Y: | 18.77 | Insider Trans: | -10.13% | Shs Float: | 256.90M | Perf Month: | -11.96% |
| Income(ttm): | -479.80M | PEG: | - | EPS next Q: | 4.05 | Inst Own: | 92.75% | Short Float: | 1.43% | Perf Quarter: | -13.64% |
| Revenue(ttm): | 10.62B | P/S: | 9.65 | EPS this Y: | -96.45% | Inst Trans: | -0.26% | Short Ratio: | 2.81 | Perf Half Y: | -16.36% |
| Book/sh: | 60.65 | P/B: | 6.55 | EPS next Y: | 3368.96% | ROA: | -2.18% | Short Interest: | 3.67M | Perf Year: | -0.74% |
| Cash/sh: | 25.33 | P/C: | 15.68 | EPS next 5Y: | 12.20% | ROE: | -2.99% | 52W Range: | 377.85 - 519.88 | Perf YTD: | -2.36% |
| Dividend Est.: | - | P/FCF: | - | EPS past 5Y: | 11.42% | ROI: | -2.77% | 52W High: | -23.58% | Beta: | 0.40 |
| Dividend TTM: | - | Quick Ratio: | 2.20 | Sales past 5Y: | 27.16% | Gross Margin: | 86.11% | 52W Low: | 5.14% | ATR (14): | 15.87 |
| Dividend Ex-Date: | - | Current Ratio: | 2.47 | EPS Y/Y TTM: | -113.76% | Oper. Margin: | -2.90% | RSI (14): | 24.09 | Volatility: | 3.99% 2.54% |
| Employees: | 5400 | Debt/Eq: | 0.11 | Sales Y/Y TTM: | 10.96% | Profit Margin: | -4.52% | Recom: | 1.89 | Target Price: | 507.93 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.11 | EPS Q/Q: | 0.82% | Payout: | 0.00% | Rel Volume: | 4.64 | Prev Close: | 396.64 |
| Sales Surprise: | 3.22% | EPS Surprise: | 7.41% | Sales Q/Q: | 11.86% | Earnings: | Nov 04 AMC | Avg Volume: | 1.31M | Price: | 397.27 |
| SMA20: | -13.06% | SMA50: | -15.61% | SMA200: | -13.19% | Undervalued: 27.86% | Volume: | 6,052,103 | Change: | 0.16% | |
Graham Classic formula value: -58.79
(P/E=8 * 1g) Min value: -36.1
(current P/E * 2g) Max value: -43.6
Average value: -46.16
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.